Saturday, October 31, 2026

Moderna Stock Bearish By 3% So Far On Tuesday

ViaNews Editorial Team

December 15, 2020

Moderna Stock Bearish By 3% So Far On Tuesday

Shares of Moderna fell 3.25% to $150.03 at 11:10 EST on Tuesday, following yesterday's downward trend. The Nasdaq Stock Market is jumping 0.74% to $12,532.50, following yesterday's upward trend, This seems, so far, a somewhat positive trend exchanging session today.

Moderna's last close was $155.07, 18.98% below its 52-week high of $178.50.

News about Moderna today

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to today's article on Bloomberg Quint, "Once the U.S. grants authorization, advisers to the Centers for Disease Control and Prevention must meet, as they did last week on Pfizer's vaccine, to give Moderna's shot the green light and provide offer specific recommendations for use and monitoring. ", "The shot must be kept extremely cold and requires special freezers to transport, while Moderna's can be kept in more traditional cold storage."

Moderna vaccine found safe, effective before key FDA review. According to today's article on Bloomberg Quint, "In addition, there were two cases of serious facial swelling in vaccine recipients that Moderna determined were related to vaccination. ", "The shot must be kept extremely cold and requires special freezers to transport, while Moderna's can be kept in more traditional cold storage."

Moderna shares up in premarket as FDA calls covid-19 vaccine 'highly effective'. According to today's article on MarketWatch, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. "

Moderna's Sales

Moderna's sales growth is 1428.1% for the present quarter and 13065.3% for the next. The company's growth estimates for the current quarter is a negative 48.6% and positive 565.7% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $150.03 at 11:10 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way above its 50-day moving average of $106.15 and way higher than its 200-day moving average of $77.98.

Previous days news about Moderna

Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "If the U.S. doesn't lock in the full 400 million extra doses, it could free up capacity for Moderna to sell more supply to other countries, potentially at a higher price.", "If it reaches the higher end of that range, Moderna could meet most of the U.S. demand for a coronavirus vaccine, Morgan Stanley analyst Matthew Harrison said in a note to clients on Dec. 8."

Moderna says U.S. to buy 100 million additional vaccine doses. According to Bloomberg Quint on Fri Dec 11, "Moderna said Friday that the order, worth $1.65 billion, would be delivered during the second quarter of 2021. ", "As part of Operation Warp Speed, the U.S. initiative to rapidly develop and secure vaccines for Covid-19, the U.S. has the option to buy another 300 million doses from Moderna at a fixed price of $16.50 per shot, the company said. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com